Phase 3 Readout
REGN: Phase 3 Topline: An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Dupilumab in Patients ≥
October 7, 2026. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- October 7, 2026
- Company
- REGENERON PHARMACEUTICALS, INC. (REGN)
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 3 Readout~month
Phase 3 Topline: An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Dupilumab in Patients ≥
- Indication
- Atopic Dermatitis
Other upcoming events for REGN
Phase 2 StartPhase 2 Start: A Phase 1/2 Open-Label, Safety and Efficacy Study of Neoadjuvant Fianlimab (Anti-LAG-3 Antibody) in
Phase 1 StartPhase 1 Start: A Master Protocol for a Phase 1b Double-Blind, Randomized Study to Assess the Safety, Tolerability,
Phase 1 StartPhase 1 Start: An Open-Label, Multi-Center Phase I Study to Investigate the Safety and Tolerability of REGN17235 in
Phase 3 ReadoutPhase 3 Topline: A Randomized, Open-Label, C5 Inhibitor-Controlled Study to Evaluate the Efficacy and Safety of Pozel